Last updated: July 21, 2026
Mallinckrodt IP v. Mylan (1:16-cv-01115) Litigation Summary, Patent Scope, and Generic Risk Analysis
Mallinckrodt IP secured a published federal-case docket for its IP dispute against Mylan Laboratories Ltd. under case number 1:16-cv-01115. The record can be analyzed only to the extent of what is confirmable from the publicly indexable docket facts: the venue and parties are identified, but the patent list, asserted claims, filing sequence (Hatch-Waxman Orange Book pathway), and the case outcome are not provided in the prompt. With those essential litigative details missing, a complete and accurate litigation summary cannot be produced.
What patents are asserted in Mallinckrodt IP v. Mylan 1:16-cv-01115?
A litigation summary for a specific ANDA-based dispute must state, at minimum, the Orange Book-listed patents asserted, including patent numbers, expiration dates, and claim categories (composition, formulation, method-of-use, manufacturing, or polymorph). The prompt does not include asserted patent identifiers or claim mapping, so the patent-protection analysis cannot be completed without introducing unverifiable content.
Which Orange Book patents are in suit?
No asserted patent numbers are included in the provided input.
Are the asserted claims composition, method-of-use, or formulation?
No claim-type information is included in the provided input.
What is the procedural timeline for 1:16-cv-01115 (filings, motions, and rulings)?
A credible docket timeline requires dates for: complaint filing, answer, Rule 12 motions, claim construction (Markman), summary judgment, trial (if any), and final judgment/consent decree/settlement. The prompt provides only the case number and party names, without milestone dates or dispositions.
When was the complaint filed and what was the relief sought?
The prompt does not include the complaint filing date or requested remedies.
Were there Markman proceedings or dispositive motions?
No procedural events are provided in the prompt.
What was the case outcome (judgment, dismissal, settlement, or ongoing)?
No final disposition is provided in the prompt.
What Paragraph IV arguments did Mallinckrodt IP make against Mylan?
Paragraph IV litigation analysis requires at least one of the following: infringement theory, invalidity theory, willfulness allegations, and the asserted §271(e)(2) framework tied to a specific ANDA paragraph. The prompt contains no ANDA paragraph details, no infringement/invalidity positions, and no claim-construction results.
How did Mallinckrodt IP allege infringement?
Not provided.
What invalidity grounds did Mallinckrodt IP rebut or did Mylan raise?
Not provided.
How strong is the patent estate for Mallinckrodt IP in this dispute?
A strength assessment depends on the asserted patent set and their stand-alone legal robustness (expiration window, prosecution history, claim breadth, prior art, and validity rulings in the same or related cases). Without the patent list, no strength rating can be made without fabricating details.
Patent expiration and remaining exclusivity window
Not provided.
Common infringement vectors (formulation, polymorph, device, dosing)
Not provided.
What generic launch and FDA pathway risk does this litigation create for Mylan?
ANDAs drive risk based on (1) the effective date of approval, (2) design-around options (different polymorph, different excipient system, different manufacturing steps), and (3) whether the litigation ended in a court judgment or settlement with launch-date limits. None of those facts are included.
If Mylan’s ANDA was approved, what launch date was targeted?
Not provided.
Were there launch-date stipulations in settlement terms?
Not provided.
Does the case affect multiple strengths or dosage forms?
Not provided.
What settlement or consent judgment terms were reached in 1:16-cv-01115?
A settlement analysis requires the docket’s final resolution instrument, such as a consent judgment, stipulated dismissal, or settlement agreement with key terms (early entry, forfeiture, covenant-not-to-sue, payment, timing). No resolution documents or terms are included.
Did Mallinckrodt win or did Mylan secure a favorable ruling?
Not provided.
Were there covenant-not-to-sue boundaries (scope limits, carve-outs)?
Not provided.
How does this case compare with other Mallinckrodt IP v. generic company litigations?
Comparison needs either (a) shared asserted patents across cases or (b) differences in asserted claims, court rulings, or settlement outcomes. The prompt does not provide any related-case identifiers, asserted patents, or outcomes.
Do similar patents appear across Mallinckrodt v. other generics?
Not provided.
Did courts reach the same claim-construction outcomes?
Not provided.
Key Takeaways
- The prompt identifies the case as Mallinckrodt IP v. Mylan Laboratories Ltd., 1:16-cv-01115, but it does not provide the litigative facts required for a complete and accurate patent and exclusivity analysis.
- A defensible litigation summary for a Hatch-Waxman dispute must include the asserted patent numbers, procedural milestones, and case disposition, none of which are included here.
- Without asserted patents and docket outcome details, no reliable conclusions can be made about infringement/invalidity arguments, settlement terms, or generic launch risk.
FAQs
- What patents were Orange Book-listed and asserted in Mallinckrodt IP v. Mylan (1:16-cv-01115)?
- What was the final disposition in 1:16-cv-01115 and did it include a consent judgment?
- Did the court enter claim construction findings (Markman) affecting infringement or validity?
- Did Mylan’s filing correspond to a specific ANDA paragraph (IV) and what was the statutory basis pleaded?
- What launch-date or entry restrictions did the parties agree to in any settlement tied to the case?
References
- (No citeable sources were provided in the prompt.)
